Global Latent TB Testing Market Outlook
Revenue, 2024
$622M
Forecast, 2034
$1.10B
CAGR, 2025 - 2034
5.9%
The Latent TB Testing industry revenue is expected to be around $658.5 million in 2025 and expected to showcase growth with 5.9% CAGR between 2025 and 2034. The increasing demand for Latent TB Testing shows how national TB control programs view this test as their main strategic priority because TB screening programs expand and people become more aware of latent TB infection risks in vulnerable groups and healthcare systems implement tougher occupational health screening requirements. The two main end user groups for revenue generation are Diagnostic Laboratories and Hospitals & Clinics because they perform 89.0% of all latent TB infection screenings and patient care activities. The Tuberculin Skin Test/TST test leads the market with $425.48 million in 2024 sales because it maintains its clinical value although interferon gamma release assay solutions are becoming more popular.
The tuberculin skin test and interferon gamma release assay blood tests under Latent TB Testing help doctors detect hidden Mycobacterium tuberculosis infections to start preventive treatment for at risk populations. The tests operate within standard laboratory systems and enable large scale public health programs while providing data for making informed decisions across different healthcare settings. The tests find their main use in migrant health checks and contact investigations and pre biologic and transplant assessments and healthcare worker tuberculosis surveillance. The global need for TB testing has increased because of new screening guidelines and digital result integration and focused testing programs in areas with high tuberculosis prevalence.
Market Key Insights
The Latent TB Testing market will expand from $621.8 million in 2024 to reach $1.10 billion during 2034. The market will expand at a 5.9% annual rate because of increasing requirements from Household Contacts and People with HIV and Diagnostic Laboratories.
QIAGEN, Revvity (Oxford Immunotec), and bioMérieux are among the leading players in this market, shaping its competitive landscape.
The Latent TB Testing market depends on the United States and China as its leading customer bases which will experience growth at 3.8% to 5.7% CAGR from 2024 to 2030.
The market research predicts Brazil, South Africa and Indonesia will experience the highest growth rates at 6.8% to 8.1% CAGR.
Transition like Shift Toward Blood-Based Assays has greater influence in U.S. and China market's value chain; and is expected to add $22 million of additional value to Latent TB Testing industry revenue by 2030.
.The Latent TB Testing market will experience $481 million growth during 2024-2034 while manufacturer focus on People Living with HIV & Others Application will drive increased market penetration.
With
escalating global tb elimination initiatives and expanding high-risk population screening programs boosting latent tb testing adoption, and
Advancements in IGRA-based TB diagnostics enhancing accuracy and scalability of latent tb testing workflows, Latent TB Testing market to expand 77% between 2024 and 2034.
Opportunities in the Latent TB Testing
European governments need to establish standardized refugee health screening protocols because migration routes are also expanding while reception centers and border clinics require fast Latent TB Testing methods. The new digital IGRA platforms unite automated analyzers with cloud connectivity to support telemedicine services and centralized quality control and cross country data exchange. The worldwide IGRA test market will reach 299.80 million in revenue by 2030 because migrant focused European applications will drive the most significant regional expansion through public private partnerships that upgrade current screening systems.
Growth Opportunities in North America and Asia-Pacific
The adoption of Latent TB Testing in North America results from immigration rules and workplace health checks and specialized care for immunocompromised patients which makes diagnostic laboratories the primary users of advanced latent tuberculosis testing solutions because they handle large test volumes from hospitals and retail clinics and public health programs. The main business opportunities involve expanding interferon gamma release assay systems for large scale testing and developing latent TB infection screening tools that work with electronic health records and population health analytics platforms and providing adaptable service options for reference laboratories across different regions. The TB diagnostics market requires companies to differentiate their products through precise assay results and automated testing systems and dependable service delivery because established manufacturers and national lab networks and digital health companies provide remote ordering and result management and clinical decision support services. The TB diagnostics segment requires companies to focus on assay precision and automation and service dependability because established manufacturers and national lab networks and digital health companies already compete in the market. The TB diagnostics market will experience future growth because of new medical guidelines that recommend blood tests over skin tests for specific high risk groups and public health laboratory funding and initiatives to detect latent infections before they become active.
The Asia Pacific region experiences growing Latent TB Testing because of its high tuberculosis incidence rates and fast urban development and government backed TB screening initiatives which make hospitals and clinics the essential end users for national TB control programs and donor funded screening programs. The market presents two main business opportunities through affordable interferon gamma release assay solutions and testing algorithms that unite symptom evaluation with radiology and latent tuberculosis screening in decentralized facilities and through private hospital participation in migrant worker and corporate screening programs. The market competition between global TB diagnostics suppliers and regional manufacturers who use price competition and distribution networks to fight for market share makes it essential to form local manufacturing alliances and implement tender based sales strategies and complete maintenance and training programs. The healthcare spending growth and international TB elimination targets and universal health coverage expansion create structural conditions which drive ongoing investments in contemporary latent TB infection screening technology throughout secondary and tertiary care facilities.
Market Dynamics and Supply Chain
01
Driver: Escalating global TB elimination initiatives and expanding high risk population screening programs boosting Latent TB Testing adoption
The global TB elimination roadmaps have also led governments and health systems and donors to focus on detecting latent tuberculosis infection at an earlier stage which has also created rising demand for Latent TB Testing throughout developed and emerging markets. The update of national strategic plans leads to budget reallocation for preventive TB diagnostics which includes Latent TB Testing as part of tuberculosis screening systems and antenatal care and public health surveillance platforms. The implementation of systematic screening for healthcare workers and migrants and HIV patients and biologic therapy initiators has also created rising test demand throughout hospital networks and occupational health programs. The need for standardized testing protocols among these groups has also forced laboratories and clinics to select Latent TB Testing solutions and TB blood test platforms that offer high scalability. The TB diagnostic market undergoes transformation because providers who deliver precise high volume tests according to new clinical standards will also achieve success.
The clinical performance of Latent TB Testing has also improved through fast paced interferon gamma release assay development which provides better specificity than the tuberculin skin test and reduces BCG vaccinated false positive results. The new IGRA platforms combine automated systems with standardized reagents and laboratory information system connectivity to perform high volume TB blood tests with consistent quality in reference and centralized laboratories. The new technology systems decrease human error during testing while reducing analysis duration and enabling remote TB diagnostic operations which enhance large scale screening programs and pre biologic evaluations and workforce health monitoring through dependable results.
02
Restraint: Limited healthcare budgets and reimbursement barriers slow adoption of advanced Latent TB Testing solutions worldwide
Public health budgets face restrictions which combined with irregular payment rates for diagnosis force hospitals to select affordable tuberculin skin tests instead of interferon gamma release assays thus controlling prices but restricting revenue expansion. The combination of low cost tuberculin skin tests with inconsistent reimbursement rates for TB diagnosis forces hospitals to delay their transition to new Latent TB Testing platforms which restricts their ability to grow revenue despite ongoing disease prevalence. The combination of short term procurement cycles and fragmented donor funding in low and middle income countries leads to unstable demand patterns which prevent long term investments in assay development and commercial expansion.
03
Opportunity: Expanding occupational screening of healthcare workers in US hospitals boosts IGRA based Latent TB Testing and Primary care delivery of Latent TB Testing in Indias urban slums reaches underserved adult populations
The United States has implemented stronger occupational health rules which require annual TB screening for nurses and physicians and all ancillary staff members thus creating ongoing need for precise Latent TB Testing. Hospital systems now select the IGRA test instead of the tuberculin skin test because it provides single visit testing and better accuracy for BCG vaccinated personnel. The IGRA testing market will expand from 196.30 million in 2024 to 299.80 million by 2030 at a 7.31% annual growth rate which makes IGRA based occupational health programs the fastest expanding testing segment in this .
The national and municipal TB programs of India conduct systematic Latent TB Testing through their primary care clinics and mobile outreach services which serve the densely populated urban slums. The combination of affordable tuberculin skin test methods and new point of care diagnostic tools allows for extensive TB screening of communities while digital tracking systems help maintain patient contact. The global tuberculin skin test market will expand from 425.48 million in 2024 to 578.71 million by 2030 with community based testing expected to generate the most significant increase in adult latent tuberculosis infection detection.
04
Challenge: Operational and infrastructure gaps restrict large scale Latent TB Testing deployment in high burden emerging markets
The implementation of guideline recommended Latent TB Testing faces barriers in high burden regions because their laboratory networks are insufficient and their cold chain logistics are unreliable and they lack enough trained technicians. The current situation results in insufficient testing rates and unmet screening targets and underused installed analyzers which decreases recurring consumables revenue and reduces manufacturer investment in local distribution and service development and delays the adoption of decentralized point of care TB diagnostics.
Supply Chain Landscape
1
IGRA Test Components
QIAGENBeijing Wantai BiopharmaceuticalSD BIOSENSOR
2
Diagnostics Manufacturers
QIAGENRevvitybioMrieux
3
TB Diagnostics Distribution
bioMrieuxSD BIOSENSORBeijing Wantai Biopharmaceutical
4
End-Users
Hospitals and clinicsPublic health laboratoriesOccupational health screening programs
1
IGRA Test Components
QIAGENBeijing Wantai BiopharmaceuticalSD BIOSENSOR
2
Diagnostics Manufacturers
QIAGENRevvitybioMrieux
3
TB Diagnostics Distribution
bioMrieuxSD BIOSENSORBeijing Wantai Biopharmaceutical
4
End-Users
Hospitals and clinicsPublic health laboratoriesOccupational health screening programs
Use Cases of Latent TB Testing in Household Contacts & People with HIV
Household Contacts : The national tuberculosis screening programs rely on Latent TB Testing of household contacts of tuberculosis patients through tuberculin skin test deployment in primary care and community campaigns yet IGRA blood tests gain popularity in urban and high income region's because they remain independent from BCG vaccination effects and minimize false positive results. The population of close contacts represents the biggest and most foreseeable customer base because public health guidelines require complete testing of all contacts within a specific time frame following index case detection followed by prophylactic treatment for confirmed latent TB infection cases. The majority of programs use a staged approach because tuberculin skin tests generate 68.43% of total demand but IGRAs generate 31.57% so they start with skin tests for initial screening followed by interferon gamma release assays for at risk or equivocal cases to enhance specificity and treatment decision making. The contact investigation market follows QIAGEN because it offers QuantiFERON solutions and comprehensive training programs for centralized laboratories while Revvity maintains its market share through T cell based assays that some specialists choose for pediatric contact testing and SD BIOSENSOR and Beijing Wantai Biopharmaceutical expand their market presence through their user friendly assay kits. bioMrieux maintains its market leadership through its automated testing solutions and quality control systems and data connection tools which enable laboratories to handle numerous samples during extensive household contact screenings.
People with HIV : The clinical value of Latent TB Testing for HIV patients becomes significant because it reveals hidden infections before they develop into dangerous conditions while IGRAs have become preferred over skin tests because immunosuppression weakens skin reactions and hides tuberculosis infections. The healthcare sector which brought in USD 218.93 million through associated services during 2024 expects to achieve 4.1% annual growth until 2030 will continue to integrate TB screening into HIV treatment protocols through initial testing at diagnosis and scheduled follow up assessments in high risk region's. QIAGEN leads the market through its adaptable blood collection methods and proven testing protocols for immunocompromised patients and its broad range of clinical data that guides prophylactic treatment decisions. The company Revvity expands its market share through its sensitive spot based platforms which multiple tertiary medical centers use to diagnose complicated cases with multiple health conditions. SD BIOSENSOR together with Beijing Wantai Biopharmaceutical Company work to increase tuberculosis testing availability in underserved region's through their affordable assay kits which operates in HIV clinic associated decentralized laboratories. The company bioMrieux enables facilities to manage TB and HIV infections through its complete solution of analyzers and informatics systems which unite different infectious disease tests into one operational process.
Diagnostic Laboratories : The diagnostic laboratory sector represents the biggest market segment for Latent TB Testing because it produced $334.64 million in revenue during 2024 and experts predict it will expand at 7.3% annually until 2030 because health systems adopt centralized TB testing and implement automated IGRA systems. The facilities operate two testing services which include manual tuberculin skin test reading and blood based IGRAs but their growth stems from high throughput analyzers that perform batch testing and maintain strict quality standards and system integration. The QuantiFERON portfolio from QIAGEN leads the market through its validated tests and wide regulatory approval and excellent technical assistance for large reference labs. The specialist centers choose Revvity because they need flexible plate formats and detailed immune response analytics. The competitive advantage of bioMrieux stems from its ability to integrate IGRA testing into multi assay platforms which run TB tests alongside other infectious disease and immunology assays. SD BIOSENSOR and Beijing Wantai Biopharmaceutical Company achieve market growth through their affordable assay kits and customized test menus which help smaller laboratories switch from manual testing methods. The 2024 Latent TB Testing market from academic and research institutions amounts to $41.22 million with a projected 6.4% annual growth rate. The diagnostic laboratories work with academic and research institutions to conduct clinical trials and method validation studies which boosts visibility for top manufacturers and drives development of advanced latent TB test technologies.
Recent Developments
The development of Latent TB Testing methods shows increasing use of interferon gamma release assays because these tests provide better results for screening tuberculosis in people at high risk and immigrants. The market leaders dedicate their resources to develop automated diagnostic systems and high capacity laboratory equipment which enables large scale latent tuberculosis infection screening. The main industry development involves uniting latent TB diagnostic tests with preventive healthcare programs which follow national TB elimination plans.
October 2023 : The WHO Global Tuberculosis Report 2023 demonstrated that the actual number of latent tuberculosis infections exceeds the current testing capacity for latent TB so the organization demands increased testing capabilities for IGRA tests and tuberculin skin tests. The directive will drive more funding for latent TB diagnostic technologies while strengthening national TB screening programs across the world.
September 2023 : At the United Nations High Level Meeting on Tuberculosis, UN member states adopted a political declaration committing to significantly scale up Latent TB Testing and TB preventive treatment by 2027, which is likely to accelerate funding and policy support for latent tuberculosis infection screening, expand the use of advanced IGRA based solutions, and underpin sustained demand growth in the global Latent TB Testing market.
Impact of Industry Transitions on the Latent TB Testing Market
As a core segment of the Medical Device industry,
the Latent TB Testing market develops in line with broader industry shifts.
Over recent years, transitions such as Shift Toward Blood Based Assays and Integration Into Routine Screening have redefined priorities
across the Medical Device sector,
influencing how the Latent TB Testing market evolves in terms of demand, applications and competitive dynamics.
These transitions highlight the structural changes shaping long-term growth opportunities.
01
Shift Toward Blood Based Assays
The shift from traditional tuberculin skin tests to interferon gamma release assay blood tests for latent TB detection is revolutionizing the healthcare landscape, particularly in high burden and low incidence regions. This transition is not only streamlining laboratory operations but also driving demand for automated analyzers and digital reporting systems that enhance integration with hospital information systems. As occupational health providers in sectors like mining and manufacturing adopt these advanced screening methods, the focus on accuracy and regulatory compliance intensifies. Strategically, this transition is projected to inject an additional $27 million into the latent TB testing market by 2030, underscoring its significant impact on the value chain in the U.S. and China. This industry transition is expected to add $22 million in the industry revenue between 2024 and 2030.
02
Integration Into Routine Screening
The practice of Latent TB Testing has evolved from occasional testing of high risk populations to become a standard part of primary care services and national tuberculosis control and elimination programs. The integration of tuberculosis screening prompts into electronic medical records enables family physicians and HIV clinics and immigration services to perform routine latent tb infection tests. The new approach enables better detection of patients who need preventive therapy while improving their ability to finish their prophylactic treatment and drives pharmaceutical companies to create enhanced rifamycin based treatments for disease prevention.